focus -WSS

focus

author：comprehensive 2025-09-27 09:55:14 - browse：27983

Abbott's heart device TriClip on a gradient dark blue background — coverage from STAT — The device is called the TriClip, and it addresses a disease called tricuspid regurgitation: a heart condition that causes blood to leak backward through the tricuspid heart valve. Illustration: STAT; Photo: Courtesy Abbott

An advisory panel to the Food and Drug Administration voted in favor of a new device from Abbott meant to treat patients with tricuspid heart valve disease. All but one of the 14 panelists said the treatment’s benefits outweighed its risks. The FDA tends to follow advisory panel recommendations.

“If we can help symptoms with this at a low cost in terms of risk, I think it makes a lot of sense,” said James Blankenship, a panelist and cardiologist at the University of New Mexico.

The device is called the TriClip, and it addresses a disease called tricuspid regurgitation: a heart condition that causes blood to leak backward through the tricuspid heart valve. The condition impacts 1.6 million people in the United States. Symptoms include fatigue, swelling, and atypical heart rhythms. In severe cases, the condition can lead to heart failure.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Activists slam private health insurers over coverage restrictions
Next article： Readout LOUD Podcast: Legal insider trading, booming biotech stocks

leisure time

WSS

In search for therapies for solid tumors, companies turn to claudin

International team creates first chimeric human

The health care issue Democrats can’t solve: hospital reform

Why getting cancer drugs just got harder for rural patients

Live blog: Hearing on CRISPR

Bill would allow buprenorphine prescription for addiction via telehealth

Wikipedia

focus

knowledge

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

The health care issue Democrats can’t solve: hospital reform

FDA approval of Sarepta Duchenne genetic therapy gives me hope

A Q&A with Aletha Maybank, AMA’s chief health equity officer

How one medical school became remarkably diverse

How to fix the rural physician shortage in the U.S.

Tori Bowie and the unacceptable rates of Black maternal death

Kidney transplant patients stopped immunosuppressants in trial

In age of alternative facts, a scholarly course on calling out crap

The health care issue Democrats can’t solve: hospital reform

leisure time

Clinical trials giant ICON acquires HumanFirst

Brain injuries and the importance of a second opinion

Abortion pill mifepristone to soon be dispensed at CVS, Walgreens

Brain injuries and the importance of a second opinion

In Gaza, a nonprofit 3D prints tourniquets and stethoscopes

Obesity now affects over 1 billion people worldwide, study finds

explore

leisure time

explore

leisure time